Targacept Reports Positive Schizophrenia Drug Study

Targacept has conducted a study on its schizophrenia drug and received positive evaluation results.

Targacept has reported positive results from a Phase II proof-of-concept trial evaluating TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.

TC-5619 was well-tolerated and met the primary efficacy outcome measure, the Groton Maze Learning Task – a computerised test designed to assess executive function. TC-5619 is a highly selective alpha7 neuronal nicotinic receptor modulator.

The double-blind and placebo-controlled trial was conducted at seven sites in the US and 12 sites in India.

In the study, 185 patients meeting DSM-IV criteria for schizophrenia and taking stable